Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to slow stomach cancer progression

NCT ID NCT07432295

Recruiting now Disease control Sponsor: I-Mab Biopharma US Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 and PD-L1) will receive either the new combo or standard treatment alone. Researchers will track side effects and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
givastomig (a targeted antibody) combined with nivolumab (immunotherapy) and chemotherapy
What this could lead to
If it works, this could point toward a more effective first-line treatment for people with advanced stomach or esophageal cancer that expresses certain proteins.
What could go wrong
This is an early Phase 2 trial with only 180 participants, so results may not apply to everyone. Adding a new drug also raises unknown side effect risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus cancer esophageal adenocarcinoma gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER ESOPHAGEAL ADENOCARCINOMA GASTRIC CANCER GASTROESOPHAGEAL JUNCTION CARCINOMA METASTATIC CANCER SOLID TUMOR

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • I-MAB Site 1005

    RECRUITING

    Duarte, California, 91010, United States

  • I-Mab Site - 4001

    NOT_YET_RECRUITING

    Kashiwa, Japan

  • I-Mab Site 1002

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • I-Mab Site 1016

    RECRUITING

    Goodyear, Arizona, 85338, United States

  • I-Mab Site 2001

    RECRUITING

    Beijing, China

  • I-Mab Site 4005

    RECRUITING

    Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.